Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.
Inflamm Bowel Dis 17(1):127-40 (2011) PMID 20848523
Adalimumab is indicated for the treatment of moderately to severely active Crohn's disease (CD). A systematic analysis of risks and benefits of adalimumab versus traditional non-biologic therapies for patients refractory to non-biologic therapy is lacking.
DOI: 10.1002/ibd.21341
Version: za2963e q8za1 q8zb5 q8zc4 q8zd7 q8zed q8zfb q8zg2